The Neuropathobiology of Primary HIV-1 Infection
原发性 HIV-1 感染的神经病理学
基本信息
- 批准号:8033299
- 负责人:
- 金额:$ 16.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAcuteAffectAnti-Retroviral AgentsArtsBiological AssayBiological MarkersBloodBlood - brain barrier anatomyBrainBrain InjuriesCentral Nervous System InfectionsCerebrospinal FluidCerebrumCharacteristicsCholineChronicCitiesClinicalCognitiveComplicationCreatineDetectionDevelopmentDiseaseEarly treatmentEtiologyEventEvolutionExposure toExtravasationFoundationsFunctional disorderFutureGlutamatesGoalsHIVHIV InfectionsHIV-1HumanImmuneImmune responseImpaired cognitionImpairmentIndividualInfectionInflammationInjuryIntestinesInvestigationLaboratoriesLamina PropriaLeadLifeLongitudinal StudiesMagnetic ResonanceMagnetic Resonance SpectroscopyMeasurementMeasuresMediatingMethodsModelingMonitorMorbidity - disease rateMotorNatural HistoryNervous System TraumaNervous system structureNeuraxisNeurocognitiveNeurologicNeurologic SymptomsNeuronal DysfunctionNeuronal InjuryNeuropathogenesisNeuropsychological TestsPathogenesisPatientsPatternPerformancePharmaceutical PreparationsPlasmaProcessProtonsRNAResearchResearch PersonnelSamplingSiteStagingStudy SubjectSystemic diseaseTechnologyTimeTissuesTropismViralViral Load resultVirusVirus DiseasesWhite Blood Cell Count procedureWorkantiretroviral therapybrain tissuecohortfollow-upimmune activationimprovedindexinginflammatory markermyoinositolneuroprotectionpreventprogramsrepositoryresponsetreatment effecttreatment strategy
项目摘要
DESCRIPTION (provided by applicant): The proposed research focuses upon events in the central nervous system (CNS) during the earliest weeks and months after initial acquisition of HIV infection, collectively defined as primary HIV infection (PHI). HIV enters the CNS in the earliest stages of infection, and the CNS is a site of persistent viral infection throughout the chronic stages of disease. The underlying hypothesis of this proposal is that initial viral neuroinvasion is important in the neuropathogenesis of HIV, leading to the foundation of persistent and compartmentalized CNS infection, and initiating the process of brain injury. The investigators will longitudinally study 75 subjects presenting during PHI to study the course of host immune and neurological responses and features of cerebrospinal fluid (CSF) HIV quasispecies beginning during this period. The first aim is to understand the relationship between viral burden, early host inflammation, and tissue injury in the CNS, through measurement of CSF markers of inflammation, immune response, and neuronal injury, cerebral metabolites by high-field (4 Tesla) magnetic resonance spectroscopy, and neuropsychological testing. The second aim is to investigate the establishment of compartmentalized CNS infection through use of the heteroduplex tracking assay to detect HIV quasispecies sequence differences between and within CSF and plasma, and through measurement of viral replicative capacity and coreceptor utilization to define the character of early HIV species in each compartment. The final aim is to describe the effect of antiretroviral therapy initiated during PHI on the course of CNS inflammation and neurological responses. This study establishes a cohort for extended follow-up and a repository of banked longitudinal samples for future studies. Our proposed approach will provide crucial information about the clinical importance of early HIV in the nervous system; if immunoactivation-mediated brain injury or the establishment of compartmentalized CNS infection occurs during PHI, early treatment with immune- modulating or antiretroviral medications may provide previously unrecognized long-term neuroprotection. Similarly, detection of beneficial effects of treatment on the CNS during PHI has the potential to profoundly influence treatment strategies in early HIV. The overall goal of this proposal is to ameliorate or prevent HIV-related CNS damage through improved understanding of the early effects and treatment of HIV in the nervous system. Central nervous system (CNS) impairment remains a major complication of HIV-1 infection, and has the potential to affect at least 20% of the 40 million people worldwide who are living with HIV-1. Clarification of the time course of establishment of CNS infection and neurological injury will contribute to an understanding of the significance of the earliest stages of HIV-1 infection in the neuropathogenesis of AIDS. In addition, revealing the early effects of antiretroviral treatment in the CNS may provide a new rationale for initiating antiretroviral therapy in early HIV-1 infection.
描述(由申请人提供):拟定研究的重点是首次获得HIV感染后最初数周和数月内中枢神经系统(CNS)的事件,统称为原发性HIV感染(PHI)。HIV在感染的最早阶段进入CNS,并且CNS是贯穿疾病的慢性阶段的持续病毒感染的部位。该建议的基本假设是,最初的病毒神经侵入在HIV的神经发病机制中是重要的,导致持续性和区室化CNS感染的基础,并启动脑损伤的过程。研究者将纵向研究75例在PHI期间出现的受试者,以研究在此期间开始的宿主免疫和神经系统反应的过程以及脑脊液(CSF)HIV准种的特征。第一个目的是了解病毒负荷,早期宿主炎症和CNS组织损伤之间的关系,通过测量炎症,免疫反应和神经元损伤的CSF标志物,高场(4特斯拉)磁共振波谱和神经心理学测试的脑代谢物。第二个目的是通过使用异源双链追踪试验检测CSF和血浆之间和内部的HIV准种序列差异,并通过测量病毒复制能力和辅助受体利用率来确定每个隔室中早期HIV种类的特征,从而研究隔室化CNS感染的建立。最后的目的是描述抗逆转录病毒治疗期间启动的PHI对中枢神经系统炎症和神经系统反应的过程中的影响。本研究建立了一个长期随访的队列,并为未来的研究建立了纵向样本库。我们提出的方法将提供关于早期HIV在神经系统中的临床重要性的关键信息;如果在PHI期间发生免疫活化介导的脑损伤或建立区室化CNS感染,则用免疫调节或抗逆转录病毒药物进行早期治疗可能提供先前未被认识到的长期神经保护。同样,在PHI期间检测治疗对CNS的有益作用有可能深刻影响早期HIV的治疗策略。该提案的总体目标是通过改善对HIV在神经系统中的早期影响和治疗的理解来改善或预防HIV相关的CNS损伤。中枢神经系统(CNS)损伤仍然是HIV-1感染的主要并发症,并且有可能影响全球4000万HIV-1感染者中的至少20%。阐明中枢神经系统感染和神经系统损伤的时间过程将有助于理解HIV-1感染的最早阶段在AIDS神经发病机制中的意义。此外,揭示抗逆转录病毒治疗在中枢神经系统中的早期作用可能为在早期HIV-1感染中开始抗逆转录病毒治疗提供新的理论基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD W. PRICE其他文献
RICHARD W. PRICE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD W. PRICE', 18)}}的其他基金
Compartmentalized CSF viral escape and the CNS HIV reservoir
区室化脑脊液病毒逃逸和中枢神经系统艾滋病毒储存库
- 批准号:
9750826 - 财政年份:2015
- 资助金额:
$ 16.43万 - 项目类别:
Compartmentalized CSF viral escape and the CNS HIV reservoir
区室化脑脊液病毒逃逸和中枢神经系统艾滋病毒储存库
- 批准号:
9063919 - 财政年份:2015
- 资助金额:
$ 16.43万 - 项目类别:
Compartmentalized CSF viral escape and the CNS HIV reservoir
区室化脑脊液病毒逃逸和中枢神经系统艾滋病毒储存库
- 批准号:
10014060 - 财政年份:2015
- 资助金额:
$ 16.43万 - 项目类别:
Defining CNS HIV Infection in Treated Patients: Foundation for Eradication
定义接受治疗的患者中枢神经系统 HIV 感染:根除的基础
- 批准号:
8262531 - 财政年份:2012
- 资助金额:
$ 16.43万 - 项目类别:
Defining CNS HIV Infection in Treated Patients: Foundation for Eradication
定义接受治疗的患者中枢神经系统 HIV 感染:根除的基础
- 批准号:
8411590 - 财政年份:2012
- 资助金额:
$ 16.43万 - 项目类别:
Central Nervous System HIV Translational Research Training Program
中枢神经系统艾滋病毒转化研究培训计划
- 批准号:
8312637 - 财政年份:2010
- 资助金额:
$ 16.43万 - 项目类别:
Central Nervous System HIV Translational Research Training Program
中枢神经系统艾滋病毒转化研究培训计划
- 批准号:
8690975 - 财政年份:2010
- 资助金额:
$ 16.43万 - 项目类别:
Central Nervous System HIV Translational Research Training Program
中枢神经系统艾滋病毒转化研究培训计划
- 批准号:
8520397 - 财政年份:2010
- 资助金额:
$ 16.43万 - 项目类别:
Central Nervous System HIV Translational Research Training Program
中枢神经系统艾滋病毒转化研究培训计划
- 批准号:
8078847 - 财政年份:2010
- 资助金额:
$ 16.43万 - 项目类别:
Central Nervous System HIV Translational Research Training Program
中枢神经系统艾滋病毒转化研究培训计划
- 批准号:
8012332 - 财政年份:2010
- 资助金额:
$ 16.43万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 16.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 16.43万 - 项目类别:
Operating Grants














{{item.name}}会员




